NCCS has filed comments in response to a request from the Surgeon General regarding the many challenges faced by health care providers and patients regarding the complexity of medication adherence. NCCS specifically called attention to the need for payment reform and the implementation of rigorous cancer care planning to improve cancer medication adherence.
The undersigned organizations, representing cancer patients, physicians, and researchers, provide comments on the Patient-Centered Outcomes Research Institute (PCORI) Draft National Priorities for Research and Research Agenda (version 1).
The Cancer Leadership Council (CLC) urges that the Department of Health and Human Services (HHS) reconsider the approach to defining essential health benefits that is outlined in the bulletin and publish a notice of proposed rulemaking, with a 90-day comment period, that would define a national minimum uniform set of benefits, permit states some flexibility to expand the minimum benefit package, provide clarity about state benefit mandates beyond 2015, and establish a transparent process for updating the minimum benefit package.
In our comments, we offer some overarching recommendations regarding the proposed regulatory framework for defining EHB set forth in the bulletin and some specific comments on the details included within the bulletin. NCCS also looks forward to the opportunity to help the Department further refine its regulatory approach in this area.
NCCS has filed comments with the Secretary of Health and Human Services offering our advice on planned rules defining essential health benefits (EHB) under the Affordable Care Act. We have recommended that EHB should regard cancer as a chronic disease and that those diagnosed with cancer should receive care planning and coordination services.
NCCS has filed comments on proposed changes to the Common Rule which governs the consent process for those participating in clinical trials.
NCCS has filed comments on the proposed rule for a new Summary of Benefits and Coverage required by the health care reform law.
NCCS filed comments on the Food and Drug Administration's Draft Guidance for Industry and Food and Drug Administration Staff: In Vitro Companion Diagnostic Devices on October 12th, 2011. The Draft sets out a proposed framework for drug and test makers to use in developing targeted treatments and new tests to help identify patients most likely to benefit from a given treatment.
NCCS filed comments with the Department of Health and Human Services, Centers for Medicare and Medicaid Services, on September 22, in response to the proposed rule on the establishment of health insurance exchanges and qualified health plans.
NCCS submitted comments to the Department of Health and Human Services, Centers for Medicare and Medicaid Services on the proposed rule for the Medicare program, relating to payment policies under the physician fee schedule and other revisions to Medicare Part D.
Connect with us:
Facebook Twitter YouTube RSSCopyright © 1995-2012 by the National Coalition for Cancer Survivorship
1010 Wayne Avenue, Suite 770 · Silver Spring, MD 20910 · 877-NCCS-YES · info@canceradvocacy.org